Uchechukwu Chukwudi Ngwu, Silas Anayo Ufelle and Alphonsus Ogbonna Ogbuabor*
Volume4-Issue8
Dates: Received: 2023-08-13 | Accepted: 2023-08-28 | Published: 2023-08-29
Pages: 1263-1267
Abstract
Vasoclusion crisis is a major cause of morbidity and mortality in patients with Sickle Cell Anemia (SCA). There are currently a paucity of data on the hemogram response to vasoclusive crisis in patients with SCA in the Enugu metropolis. The present study is designed to determine the hemogram response to vasoclusive crisis in SCA patients compared to steady state and controls. A total of 150 subjects comprising 75 confirmed SCA patients (35 males and 40 females) aged between 16 and 30 years from Sickle Cell Clinic and 75 apparently healthy age and gender-matched controls of the Enugu State University of Science and Technology Teaching Hospital Enugu State participated in the study. Sample size was calculated using single proportion method. Ethical clearance was obtained from the Ethical Review Board of the hospital. Informed consent was obtained from subjects. Blood sample (5.0 ml) was collected from each subject and 3.0 ml was dispensed into ethylene diamine tetracetic acid tubes for estimation of the hemogram using Mindray 530-BC hemoanalyser. The hemogram revealed significant decrease (p < 0.05) in Hemoglobin (Hb) during crisis (9.17 ± 0.91 g/dl) and during stead-state (11.63 ± 0.45 g/dl) and in hematocrit (Hct) during crisis (34.80 ± 3.03%) and during steady state (34.90 ± 1.37%) compared to controls Hb (13.5 ± 0.5 g/dl) and Hct (39 ± 1.5%). The total white blood cell count (TWBC) (8.3 ± 2.0 x 109/l) significantly increased (p < 0.05) in crisis compared to TWBC (5.2 ± 1.0 x 109/l) and (5.5 ± 0.5 x 109/l) for the steady-state and controls respectively while the Platelet (PLT) significantly increased (p < 0.05) in crisis (200 ± 55.05 x 109/l) compared to PLT (164 ± 45.39 x 109/l) and (150 ± 20.0 x 109/l) for the steady-state and controls respectively. This finding provides scientific data for changes in the hemogram in sickle cell patients during crisis and steady state.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1793
Certificate of Publication
Copyright
© 2023 Ngwu UC, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
© 2023 Ngwu UC, et al. Distributed under Creative Commons CC-BY 4.0
Subject area(s)
References
- Siransy LK, Dasse RS, Adou H, Kouacou P, Kouamenan S, Sekongo Y, Yeboah R, Memel C, Assi-Sahoin A, Moussa SY, Oura D, Seri J. Are IL-1 family cytokines important in management of sickle cell disease in Sub-Saharan Africa patients? Front Immunol. 2023 Mar 9;14:954054. doi: 10.3389/fimmu.2023.954054. PMID: 36969226; PMCID: PMC10034065.
- Fome AD, Sangda RZ, Balandya E, Mgaya J, Soka D, Tluway F, Masamu U, Nkya S, Makani J, Mmbando BP. Hematological and biochemical reference ranges for the population with sickle cell disease at steady state in Tanzation. Hemato. 2022;3:82-97. doi: 10.3390/hemato3010007.
- Abubakar Y, Ahmad HR, Frauk JA. Hematological parameters of children with sickle cell anemia in steady and crisis state in Zara. Ann Tropical Pathol. 2019;10:122-125. doi: 10.4103/atp.atp_22_19.
- Luciano PMM, Albuguergue XMCC. Interleukin-6 gene polymorphisms influencing in hematological indices from sickle cell anemia patients. Brazillian J Dev. 2023;9(2):6881-6594. doi: 10.34117/bjdv9n2-030.
- Alaka AA, Alaka OO, Iyanda AA. Nitric oxide and zinc levels in sickle cell hemoglobinopathies: A relationship with the markers of disease severity. Pomeranian J Life Sci. 2023;69(1):1-12.
- Cardoso EC, Silva-Neto PV, Hounkpe BW, Chenou F, Albuquerque CCMX, Garcia NP, Silva-Junior AL, Malheiro A, Cesar P, de Lima F, De Paula EV, Fraiji NA. Changes in Heme Levels during Acute Vaso-occlusive Crisis in Sickle Cell Anemia. Hematol Oncol Stem Cell Ther. 2023 Jan 17;16(2):124-132. doi: 10.1016/j.hemonc.2021.08.002. PMID: 34450106.
- Sesti-Costa R, Costa FF, Conran N. Role of MACROPHAGES IN SICKLE CELL DISEASE ERYTHROPHAGOCYTOSIS AND ERYTHROPOIESIs. Int J Mol Sci. 2023 Mar 28;24(7):6333. doi: 10.3390/ijms24076333. PMID: 37047304; PMCID: PMC10094208.
- Tarbiah NI, Almutairi HS, Alkhattabi NA, zaher GF, Alhemadi MM, Alamni RS, Sabban AM. The role of pro-inflammatory cytokines in sickle cell disease Saudi patients. Bioscience Biotechnol Res Communication. 2021;14(3):1-6. doi: 10.21786/bbrc/14.3.15.
- Obeagu EI, Muhimbura E, Kagenderezo PB, Uwakwer SO, Nakyeyune S, Obeagu GU. An update on interferon gamma and C-reactive protein in sickle cell anemia crisis. J Biomed Sci. 2022;11(10):1-6. doi: 10.36648/2254-609X.11.10.84.
- Siransy LK, Yapo-Crezoit CCA, Diane MK, Goore S, Kabore S, Koffi-kabran B, Konate S. Th1 and Th2 cytokines pathern among sickle cell disease patients in cote d’ivore. Clin Immunol Res. 2018;2(1):1-4.
- Ogbuabor AO, Arji NG, Ngwo CU. Knowledge and determinants of hepatitis B virus testing and vaccination status among sickle cell disease patients. Intl J Pathogen Res. 2022;11(2):1-6. doi: 10.9734/ijpr/2022/v11i2206.
- Arishi WA, Alhadrami HA, Zourob M. Techniques for the Detection of Sickle Cell Disease: A Review. Micromachines (Basel). 2021 May 5;12(5):519. doi: 10.3390/mi12050519. PMID: 34063111; PMCID: PMC8148117.
- Agu NC, Ogbuabor AO, Okwuosa CN, Achukwu PU. Some serum cytokines (Adiponectin, apolipoprotein B, hsCRP, IL-6) in a cohort of type 2 diabetes mellitus patients. Intl J Health Sci Res. 2022;12(12):97-103. doi: 10.52403/ijhsr.2022121.
- Samuel OO, Ossai-Chidi LN. Serum levels of pro-inflammatory cytokine in children with sickle cell disease in River State, Nigeria. Intl J Res Report Hematol. 2018;1(2):39-45. doi: 10.9734/IJR2H/2018/43759.
- Elzubeir AM, Alobied A, Halim H, Awad M, Elfaki S, Mohammed M, Saddig AO. Estimation of serum interleukin-6 level as a useful marker for clinical severity of sickle cell disease among Sudanese patients. Intl J Multidisciplinary and Curr Res. 2017;5:642-644.
- Alagbe AE, Olaniyi JA, Aworanti OW. Adult Sickle Cell Anaemia Patients in Bone Pain Crisis have Elevated Pro-Inflammatory Cytokines. Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018017. doi: 10.4084/MJHID.2018.017. PMID: 29531654; PMCID: PMC5841944.
